Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 3:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 743 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hypertension, Pulmonary Clear all
Terminated Phase 3 Interventional Results available

A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment

NCT03689244
View directory record Official record
Conditions
Chronic Thromboembolic Pulmonary Hypertension
Interventions
Selexipag, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 85 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
32
States / cities
La Jolla, California • Los Angeles, California • Aurora, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Oct 7, 2026, 3:17 AM EDT
Withdrawn Phase 3 Interventional

Study of PAH Subjects With LTOT Use That Have Demonstrated Improved Exercise Tolerance With the Use of Inhaled Nitric

NCT03602781
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Placebo, iNO
Drug
Lead sponsor
Bellerophon Pulse Technologies
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Chicago, Illinois • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 7, 2026, 3:17 AM EDT
Withdrawn Phase 4 Interventional

Early iNO for Oxidative Stress, Vascular Tone and Inflammation in Babies With Hypoxic Respiratory Failure

NCT01891500
View directory record Official record
Conditions
Persistent Fetal Circulation Syndrome, Hypertension, Pulmonary, of Newborn, Persistent, Persistent Pulmonary Hypertension of Newborn
Interventions
Inhaled nitric oxide, Nitrogen Gas, Crossover iNO
Drug
Lead sponsor
University of Florida
Other
Eligibility
30 Minutes to 48 Hours
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Oct 7, 2026, 3:17 AM EDT
Completed Phase 2 Interventional Results available

An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients

NCT00792571
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Beraprost Sodium Modified Release
Drug
Lead sponsor
Lung Biotechnology PBC
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
3
States / cities
Torrance, California • Pittsburgh, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Oct 7, 2026, 3:17 AM EDT
Recruiting Phase 2 Interventional

Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH

NCT05937854
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension, Dyspnea
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
35 Years to 89 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
5
States / cities
Aurora, Colorado • Decatur, Georgia • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 7, 2026, 3:17 AM EDT
Not listed No phase listed Observational

Assessment of the TGF-beta Pathway and Micro-RNA in Pediatric Pulmonary Arterial Hypertension

NCT04489251
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Protein Elisa analysis, microRNA analysis, whole exome sequencing
Diagnostic Test
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
2 Years to 17 Years
Enrollment
40 participants
Timeline
2020 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Oct 7, 2026, 3:17 AM EDT
Terminated No phase listed Observational

Cardiac Metabolic Remodeling After Pulmonary Vasodilator Therapy in Pulmonary Arterial Hypertension: A Pilot Study

NCT04090866
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Right-Sided Heart Failure
Interventions
PET/MRI
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 7, 2026, 3:17 AM EDT
Terminated Phase 2 Interventional Results available

Insulin Resistance in Pulmonary Arterial Hypertension

NCT00825266
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
bosentan, Pioglitazone
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 7, 2026, 3:17 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Prospective Longitudinal Observational Cohort Study of Pregnant Women Residing at High Altitude in Bolivia

NCT07312227
View directory record Official record
Conditions
Hypertensive Disorder of Pregnancy, Pulmonary Arterial Hypertension, Intrauterine Growth Restriction
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 7, 2026, 3:17 AM EDT
Not yet recruiting No phase listed Observational

Reverse Remodeling of the Pulmonary Vasculature: a Longitudinal, Investigational Study of the Effects of Sotatercept.

NCT07487441
View directory record Official record
Conditions
Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
Franz Rischard, DO
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 7, 2026, 3:17 AM EDT
Recruiting No phase listed Observational

Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH)

NCT05462574
View directory record Official record
Conditions
Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
Interventions
No Intervention
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 7, 2026, 3:17 AM EDT
Terminated Phase 2 Interventional Results available

A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag

NCT03942211
View directory record Official record
Conditions
Sarcoidosis-associated Pulmonary Hypertension
Interventions
Selexipag, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Indianapolis, Indiana • New Orleans, Louisiana • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 7, 2026, 3:17 AM EDT
Not listed No phase listed Observational

Assessing the Utility of Submaximal CPET in Treatment Management of PAH

NCT05977933
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Shape II CPET
Device
Lead sponsor
Shape Medical Systems, Inc.
Industry
Eligibility
21 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
6
States / cities
Torrance, California • Denver, Colorado • Jacksonville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 7, 2026, 3:17 AM EDT
Completed Phase 2 Interventional

Compassionate Use of Beraprost Sodium 314d Modified Release for Patients With Pulmonary Arterial Hypertension (PAH)

NCT01966302
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
BPS-314d-MR
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 7, 2026, 3:17 AM EDT
Withdrawn No phase listed Observational

Noninvasive Cardiac Output Measurements in Patients With Pulmonary Hypertension Undergoing Exercise Testing

NCT01275703
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Oct 7, 2026, 3:17 AM EDT
Active, not recruiting Phase 2 Interventional

Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)

NCT06814145
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Sotatercept
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
23
States / cities
Phoenix, Arizona • La Jolla, California • Santa Barbara, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 7, 2026, 3:17 AM EDT
Not yet recruiting Phase 2 Interventional

Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer

NCT07793253
View directory record Official record
Conditions
Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc), Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma, Ampulla of Vater Carcinoma, Ampullary Carcinoma
Interventions
Daraxonrasib
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 7, 2026, 3:17 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

NCT05147805
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil Palmitil, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
21
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 7, 2026, 3:17 AM EDT
Completed Phase 3 Interventional Results available

BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension

NCT00910429
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Riociguat (Adempas, BAY63-2521)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 80 Years
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
8
States / cities
La Jolla, California • Sacramento, California • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 7, 2026, 3:17 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

N-Terminal Pro-brain Natriuretic Peptide Hormone and Persistent Pulmonary Hypertension

NCT00443859
View directory record Official record
Conditions
Persistent Pulmonary Hypertension of Newborn
Interventions
Not listed
Lead sponsor
Christiana Care Health Services
Other
Eligibility
Up to 6 Months
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Newark, Delaware • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Oct 7, 2026, 3:17 AM EDT
Terminated Phase 4 Interventional

Natrecor in Pulmonary Hypertension

NCT00075179
View directory record Official record
Conditions
Pulmonary Hypertension, Cancer, Lung Disease, Cardiothoracic Surgery
Interventions
Nesiritide (Natrecor), Right Heart Catheterization
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 7, 2026, 3:17 AM EDT
Not listed Not applicable Interventional

Integrating Behavioral Health and Primary Care for Comorbid Behavioral and Medical Problems

NCT02868983
View directory record Official record
Conditions
Arthritis, Asthma, Chronic Obstructive Lung Disease, Diabetes, Heart Failure, Hypertension, Anxiety, Chronic Pain, Depression, Fibromyalgia, Insomnia, Irritable Bowel Syndrome, Problem Drinking, Substance Use Disorder
Interventions
Integration
Other
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
4,025 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 7, 2026, 3:17 AM EDT
Completed No phase listed Observational

Validation of SEARCH, a Novel Hierarchical Algorithm to Define Long-term Outcomes After Pulmonary Embolism

NCT05568927
View directory record Official record
Conditions
Pulmonary Embolism, Chronic Thromboembolic Pulmonary Hypertension
Interventions
SEARCH algorithm
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
8
States / cities
Fresno, California • Irvine, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 7, 2026, 3:17 AM EDT
Withdrawn Phase 2 Interventional

Use of Inhaled Nitric Oxide to Prevent Pulmonary Hypertension Associated to Stored Blood Transfusion

NCT02217683
View directory record Official record
Conditions
Hypertension, Pulmonary, Hemolysis
Interventions
Nitric Oxide
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2016 · Synced Oct 7, 2026, 3:17 AM EDT